Potentially thrombogenic materials in factor IX concentrates.
Factor XI concentrates manufactured from human plasma and intended for therapeutic infsuion in man have been suspected for some time of being potentially thrombogenic. In the current studies, assays were carried out in vitro and in vivo for potentially thrombognic materials. It was possible to rank the various materials tested according to the amount of thromboninic material detected. For concentrates not containing heparin, there was substantial agreement between the in vivo and in vitro assays, with a coefficient of correlation of 0.77. There was no correlation between the assays for thrombogenicity and the antithrombin III content. We conclude that many presently availabel concentrates of Factor IX contain substantial amounts of potentially thrombogenic enzymes, and that this fact must be considered in arriving at the decision whether or not to use them therapeutically.
D000818:Animals; D000991:Antithrombins / Q000032:analysis; D001779:Blood Coagulation Factors / Q000032:analysis; D004789:Enzyme Activation; D004792:Enzyme Precursors / Q000032:analysis; D005164:Factor IX / Q000009:adverse effects* / Q000032:analysis / Q000592:standards; D006493:Heparin / Q000032:analysis / Q000494:pharmacology; D006801:Humans; D007531:Isoflurophate / Q000494:pharmacology; D011517:Prothrombin Time; D013923:Thromboembolism / Q000209:etiology*; D014361:Trypsin Inhibitors / Q000494:pharmacology
D000991:Antithrombins; D001779:Blood Coagulation Factors; D004792:Enzyme Precursors; D014361:Trypsin Inhibitors; D007531:Isoflurophate; D005164:Factor IX; D006493:Heparin